Назофан

Selected form

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Назофан

Quick Facts

Property	Description
Active ingredient	Fluticasone propionate
Form	Aqueous nasal spray
Pharmacological class	Corticosteroid (Glucocorticoid)
Common purpose	Reducing nasal inflammation and swelling
Origin	Synthetic (human-made)

Назофан: A Localized Anti-inflammatory Nasal Medicine

Назофан (Nasofan) is a pharmaceutical product formulated as an aqueous nasal spray intended for intranasal administration. Its active component, Fluticasone propionate, is a highly potent anti-inflammatory agent belonging to the class of corticosteroids, specifically a glucocorticoid.

This medication is designed to be a localized treatment, meaning its effects are primarily focused on the nasal lining where inflammation and swelling occur. The efficacy of this type of nasal spray is attributed to these direct topical effects rather than significant systemic absorption. The medication is often recognized for its high topical effectiveness combined with low systemic exposure, making it a option for sustained nasal management.

What is the Active Ingredient and Form?

The active agent in this single-ingredient product is the synthetic compound Fluticasone propionate. Назофан is specifically formulated as an aqueous suspension nasal spray, a feature that ensures the medication is spread consistently over the nasal mucosa.

As a glucocorticoid, Fluticasone propionate primarily acts by binding to specific receptors in nasal cells, a process that effectively shuts down multiple pathways responsible for inflammation. This class of drug is widely used due to its ability to modulate the immune system and decrease inflammation. The use of a single, highly potent active ingredient provides a clear therapeutic approach for relieving internal swelling and clearing congestion.

What Is Назофан’s General Purpose?

The primary purpose of using a medicine like Назофан is to dampen the body's over-the-top inflammatory response within the nose. This effect leads to a reduction in symptoms like internal swelling, congestion, and excessive fluid discharge.

A typical, neutral use scenario involves patients seeking long-term relief from chronic nasal discomfort that doesn't respond well to temporary decongestants. By focusing on the underlying inflammation, the medication promotes long-term comfort and improved nasal airflow over the course of treatment.

Regulatory References

Fluticasone Nasal Spray: MedlinePlus Drug Information

What side effects are possible with Назофан?

The safety profile of Fluticasone propionate nasal spray ( Назофан) is officially defined by regulatory authorities based on the classification of adverse reactions by frequency and organ system.

Adverse Reaction Classifications

The most frequently reported adverse reactions are primarily local effects, categorized as follows in official prescribing information:

Classification	Example Adverse Reaction
Very Common (Affects ge 1 in 10)	Epistaxis (Nosebleed)
Common (Affects ge 1 in 100)	Nasal dryness, Throat irritation, Headache

Local effects such as nasal irritation and changes in smell or taste are also officially classified as common. In rare instances, local infections with Candida albicans in the nose and throat have been documented.

Serious and Systemic Safety Notes

Rare and very rare adverse reactions are typically associated with systemic exposure or structural changes. These include nasal septal perforation and hypersensitivity reactions (such as anaphylaxis and angioedema). Ocular disorders like glaucoma and cataract are also classified as very rare and associated with prolonged treatment.

Systemic risks, such as adrenal suppression or Hypercorticism, are recognized primarily in the context of high doses for prolonged periods or when the medication is co-administered with certain strong enzyme inhibitors (e.g., Ritonavir). Furthermore, official safety constraints exist for specific populations; for instance, pediatric patients require monitoring due to the documented potential for growth retardation with long-term use of nasal corticosteroids. Use is also restricted in cases of recent nasal surgery or trauma due to the inhibitory effect on wound healing. This structure ensures that the risk profile, ranging from common local effects to rare systemic concerns, is formally communicated.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with this medication, whose active ingredient is beclomethasone dipropionate, primarily in the context of high doses used over a short time period, or prolonged use at higher than recommended doses.

Documented Overdose Findings

Acute overexposure from inhaling large amounts of the drug over a brief period is primarily associated with suppression of Hypothalamic-Pituitary-Adrenal (HPA) function. This HPA suppression is a measure of the body's internal stress-hormone production being reduced due to the high steroid dose. No specific emergency action is typically needed for isolated acute overexposure, as this function is expected to recover naturally within a few days.

Over the longer term, continuous use of doses higher than those recommended may result in clinically significant adrenal suppression. This is a potential serious complication, and if such use is suspected, additional systemic corticosteroid management may be required during times of stress, such as severe illness or elective surgery.

When to Seek Emergency Medical Attention

In the event that the medication is accidentally swallowed, or if someone has used excessive amounts and is showing concerning symptoms, immediate medical attention should be sought.

Regulatory documents emphasize that a potential overdose should be treated supportively with appropriate monitoring, and there is no specific antidote. Contacting a doctor, a national poisons center, or emergency services is the appropriate course of action for managing any suspected overdosage, especially if signs of illness appear.

Therapeutic Uses of Назофан

What Назофан Treats: Main Uses and Benefits

This medication is commonly used to help manage the symptomatic discomfort of seasonal hay fever and perennial (year-round) allergies, as well as non-allergic nasal inflammation.

Symptom Management and Airway Support

This medication is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to inflammatory or irritative states that interfere with daily functioning. It is generally used to help with conditions characterized by periods of heightened symptoms, such as rhinitis. It helps address symptom clusters that may become intense or disruptive, including relevant symptoms like nasal congestion, stuffiness, sneezing, nasal itching, and excessive runny nose. The therapeutic goal is to provide support that helps ease the overall symptom burden. For patients dealing with these recurrent issues, the medication contributes to improved day-to-day comfort during symptomatic periods.

Symptomatic Support for Chronic Nasal Polyps

This medication is applied in scenarios where additional management of discomfort is required for chronic conditions, specifically nasal polyposis. Its role is relevant for easing the symptoms related to polyps, and it may be part of symptomatic management used to address the potential recurrence of these growths. This provides supportive relief when symptoms interfere with routine activities and contributes to easing the overall symptom load.

Quick Fact: Relief for Nasal Congestion
Primary Focus	Nasal congestion and swelling
Main Conditions	Allergic Rhinitis (seasonal/perennial), Nonallergic Rhinitis, Nasal Polyposis
Core Symptom Relief	Stuffy nose, sneezing, itching, and runny nose
Benefit Context	Supports improved comfort during symptomatic periods

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Назофан?

This information reflects the authorized eligibility and formal contraindications for Назофан (fluticasone propionate) nasal spray, as documented in official government regulatory labeling.

Populations Authorized and Restricted

Classification	Eligible Population	Restriction/Status
Age Eligibility	Adults and children 4 years of age and older	Not recommended for children younger than 4 years, as safety and efficacy are not established.
Contraindication	N/A	Contraindicated in patients with a known history of hypersensitivity or allergy to fluticasone propionate or any inactive ingredient in the formulation.

Conditions Requiring Special Consideration

The medicine should be used with caution and medical judgment in the presence of certain clinical conditions, as use may be restricted or not recommended until the condition is resolved or evaluated:

Recent Nasal Trauma or Surgery: Patients with a recent history of nasal septal ulcers, unhealed nasal wounds, recent nasal trauma, or nasal surgery should avoid use until fully healed.
Untreated Infections: Use should be managed carefully in patients with certain active systemic infections or untreated localized infections of the nasal mucosa, such as existing or latent tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex.
Severe Hepatic Impairment: Caution is advised in patients with severe liver dysfunction, as this may lead to increased systemic exposure to the medicine.
Pregnancy and Lactation: Use during pregnancy or while breastfeeding requires a clinical assessment where the potential benefit is weighed against the potential risk. Fluticasone propionate's transfer into breast milk is not fully established.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products for Назофан (Fluticasone Propionate)

The official regulatory documentation for fluticasone propionate nasal spray details specific interactions that can affect the systemic exposure and risk profile of the drug. The primary concern is pharmacokinetic interaction due to the metabolism of fluticasone propionate by the Cytochrome P450 3A4 (CYP3A4) enzyme.

Documented Pharmacokinetic Interactions

Interaction Type	Interacting Products/Classes	Regulatory Constraint
CYP3A4 Inhibition	Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole, Cobicistat-containing products)	Co-administration is generally not recommended or should be avoided due to the significant risk of increased fluticasone propionate systemic exposure.

Co-administration with potent inhibitors such as Ritonavir is specifically documented to substantially increase plasma concentrations (AUC and Cmax) of fluticasone propionate. This increase can lead to systemic corticosteroid effects, including hypercorticism and HPA-axis suppression.

Pharmacodynamic and Other Considerations

Interaction Type	Interacting Products/Conditions	Official Note
Additive Effects	Other corticosteroids (oral, inhaled, topical)	Concomitant use increases the risk of systemic corticosteroid side effects due to cumulative exposure.
Population Risk	Severe Hepatic Impairment	Patients must be monitored for signs of increased systemic exposure, as the drug's clearance may be reduced.

No timing-based separation requirements for dosing are explicitly detailed in the interaction sections; regulatory guidance focuses on avoidance or close monitoring of these combinations.

Mechanism of Action

How Назофан Works

Fluticasone propionate, the active compound in Назофан, exerts its effects through binding to the intracellular glucocorticoid receptor (GR). This interaction constitutes the primary biological target of the compound. The drug-receptor complex then translocates into the cell nucleus, where it functions as a transcription factor, initiating the mechanistic cascade of gene modulation.

This binding event alters the pathway modulation by increasing the transcription of anti-inflammatory genes and suppressing the transcription of genes encoding pro-inflammatory mediators, including cytokines (e.g., interleukins) and chemokines. The resulting intracellular consequence is a net reduction in the synthesis and release of these inflammatory signaling molecules.

At the tissue level, this leads to the system-level physiological consequence of decreased inflammatory cell influx and suppressed activity of cells such as eosinophils and mast cells. Additionally, the drug contributes to reduced capillary permeability, limiting the extravasation of fluid and plasma proteins into surrounding tissues.

Dosage and Administration Information

Official Administration Guidelines

Назофан (Fluticasone propionate) is administered by the intranasal route only. Proper administration requires the use of a metered-dose nasal spray and adherence to specific procedural steps and dosing limits as outlined in regulatory documents.

Dosing and Frequency

Age Group	Recommended Starting Dose	Maximum Daily Dose
Adults and Children ge 12 years	Two sprays into each nostril once daily (200 mug)	Four sprays into each nostril (400 mug)
Children 4 to 11 years	One spray into each nostril once daily (100 mug)	Two sprays into each nostril (200 mug)

The recommended frequency is once daily, preferably in the morning. Once symptoms are controlled, the dose should be reduced to the minimum level necessary to maintain effective control. The medicine is not recommended for children under 4 years of age as safety and efficacy have not been established in this group.

Procedural Steps

Before using the nasal spray for the first time, the pump must be primed by pressing down and releasing it six times until a fine mist is produced. If the medicine has not been used for seven days, it must be reprimed by repeating this process.

Administration Context

Route of Administration: Intranasal only.
Timing: Preferably in the morning.
Continuous Use: Full therapeutic benefit may not be obtained for 3 to 4 days after the start of treatment, and regular usage is essential for maximum relief.

Recent Clinical Evidence

Назофан contains fluticasone propionate, an intranasal corticosteroid (INCS) used to manage symptoms associated with allergic rhinitis, commonly known as hay fever.

Efficacy in Allergic Rhinitis

Clinical evidence consistently supports the use of fluticasone propionate for both seasonal and perennial allergic rhinitis.

Nasal Symptoms: Studies evaluating the Total Nasal Symptom Score (TNSS) have shown that fluticasone propionate is associated with significant improvements compared to placebo in reducing core symptoms such as nasal congestion, rhinorrhea (runny nose), sneezing, and nasal itching.
Onset of Action: While benefits are typically observed within the first day of use, the maximum therapeutic effect in managing mucosal inflammation and achieving optimal symptom control may require continuous use for several days to over a week.

Comparative Findings

Research comparing fluticasone propionate with other INCS formulations and different classes of allergy medications provides context for its role in treatment guidelines.

Comparison	Evidence Finding
Vs. Placebo	Fluticasone propionate consistently demonstrated superior efficacy in relieving both nasal and ocular symptoms in patients with seasonal and perennial allergic rhinitis.
Vs. Other INCS	In comparative studies with other intranasal corticosteroids, fluticasone propionate showed comparable or statistically superior efficacy in reducing specific individual symptoms, such as sneezing and nasal itching, depending on the study design and drug used for comparison.
Vs. Oral Antihistamines	Intranasal corticosteroids, including fluticasone propionate, are generally considered the most effective pharmacological treatment modality for moderate-to-severe allergic rhinitis and are typically favored over oral antihistamines for managing nasal symptoms.

Additional Benefits

Beyond the direct relief of nasal symptoms, evidence suggests that the topical anti-inflammatory action of the medication may contribute to improvements in related issues. Studies assessing quality of life measures often report greater patient-perceived benefit in those using fluticasone propionate compared to placebo.

Frequently Asked Questions (FAQ)

Common questions about Назофан (FAQ)

Q: Is Назофан the same type of medicine as other common nasal sprays?

A: Official documents classify the active ingredient in the medicine as a corticosteroid, which works by reducing internal inflammation over time. This mechanism is different from common decongestant nasal sprays, which act quickly by constricting blood vessels to temporarily clear the nose.

Q: How long does the effect of one use of Назофан typically last?

A: The medicine is generally recommended for use once daily in official regulatory documentation. This frequency indicates that the intended duration of action for a single use is 24 hours.

Q: Is it possible to become dependent on Назофан?

A: Regulatory documentation indicates that this type of nasal corticosteroid medicine is not associated with dependence. Regulatory information indicates that rebound congestion is typically associated with decongestant sprays and is not a listed concern for this type of corticosteroid spray.

Q: Can Назофан be used for a common cold?

A: Official documents state that the primary purpose of the medicine is for the management of symptoms associated with allergic rhinitis (often called hay fever). The medicine is approved for use based on its defined indication.

Q: Is it safe to use Назофан every day for a long period?

A: Regulatory documents recognize that prolonged use of any corticosteroid, even in nasal form, carries recognized risks, such as potential systemic effects or ocular disorders. Official warnings note that monitoring may be recommended for patients using the medicine for several months or longer, as detailed in the regulatory precautions.

Q: Is there a feeling of burning or stinging associated with using Назофан?

A: Official documents classify nasal irritation and nasal dryness as common effects of the medicine. These general descriptions of local discomfort may include sensations such as burning or stinging.

Q: Is it described in official information if Назофан interacts with alcohol?

A: Official regulatory documents for the single-ingredient nasal spray do not list specific interactions with alcohol.

Q: Can I use Назофан with other non-prescription allergy medicines?

A: Regulatory documents list interactions with other corticosteroids and specific enzyme inhibitors, but generally do not list co-administration warnings for non-sedating oral antihistamines. Checking the label of any medicine being used is a standard precaution.

Q: Are there any food restrictions mentioned when using Назофан?

A: Regulatory information cautions that this medicine is metabolized by an enzyme also affected by certain products, such as grapefruit juice. For this reason, consumption of such products may be reviewed by a healthcare provider.

Q: Can people with high blood pressure use Назофан?

A: Official regulatory documents do not list high blood pressure as a specific contraindication or a condition requiring special caution for the use of this nasal medicine.

Q: Does Назофан have any known interactions with commonly used painkillers?

A: Official regulatory documents list specific interactions with strong CYP3A4 inhibitors (certain antiviral or antifungal medications), but do not list interactions with commonly used painkillers.

Q: Is it true that Назофан can only be used for a certain number of days in a row?

A: Regulatory documents emphasize the importance of continuous use for the maximum therapeutic effect to be achieved and maintained. The official information does not specify a short-term limit on the number of consecutive days of use, unlike some other types of nasal sprays.

Q: Do I need a prescription to get Назофан?

A: The regulatory status of the active ingredient varies by jurisdiction and product strength. In many areas, some formulations are approved for sale as over-the-counter (OTC) products.

Q: Can Назофан affect sleep or cause drowsiness?

A: Drowsiness or sleep disturbances are not listed among the very common or common side effects in regulatory documents, which reflects the low systemic absorption of the medicine.

Q: Is there a different name or brand name for the same ingredient as Назофан?

A: The active ingredient in the medicine is Fluticasone propionate. The same active ingredient may be marketed under different brand names depending on the country or specific product formulation.

Q: How does the action of Назофан differ from simple saline sprays?

A: The medicine’s action is defined as a potent anti-inflammatory effect that works at the cellular level to stop the root cause of swelling and congestion. This is fundamentally different from the mechanical washing, moisturizing, or rinsing action of simple saline solutions.

Q: Can Назофан be used to treat symptoms in the eyes, or only the nose?

A: Clinical evidence documented in regulatory sources shows that intranasal use of the medicine is associated with an improvement in both nasal and ocular symptoms (eye-related symptoms).

Q: Is 'rebound congestion' a concern with Назофан?

A: Rebound congestion, also called Rhinitis Medicamentosa, is a condition typically associated with the overuse of decongestant nasal sprays. It is typically associated with decongestant sprays and is not listed as a concern in the regulatory information for this type of corticosteroid spray.

Q: Is it described if Назофан should be used before or after clearing the nose?

A: Official patient instructions often describe the process of gently clearing the nose (for example, by blowing it) prior to using the nasal spray, which is intended to help the medicine reach the nasal lining.

Q: Are there any known interactions between Назофан and herbal supplements?

A: Regulatory guidance advises caution regarding potential interactions with herbal supplements and complementary medicines. This caution is due to the limited official information available about how these combinations might affect the medicine’s absorption or breakdown.

Q: Can elderly patients use Назофан without special precautions?

A: Official regulatory documents state that no specific dose adjustment is required for elderly patients. The need for monitoring may be considered for any patient with pre-existing conditions that affect how the drug is cleared from the body, such as severe liver impairment.

Q: Why might a doctor switch a patient from another medicine to Назофан?

A: The basis for choosing this medicine is supported by comparative clinical findings documented in official materials. These findings establish its role as an effective treatment, particularly as a preferred treatment modality over certain non-steroid alternatives for moderate-to-severe allergic rhinitis.

Q: Are there different strengths or concentrations of Назофан available?

A: Regulatory documents confirm a standard concentration of 50 mug of fluticasone propionate per spray is typically used. Patients achieve different daily dosage regimens by adjusting the number of sprays used in each nostril.

Q: Does official research cover long-term use (over 6 months) of Назофан?

A: The regulatory text references the potential for adverse effects during prolonged treatment and long-term use (for instance, the risk of ocular effects). This implies that safety data for extended use of the medicine was evaluated during its development.

Q: Do studies show if Назофан helps with sinus pressure?

A: Studies documented in regulatory information focus on the relief of core allergic rhinitis symptoms, including nasal congestion, rhinorrhea (runny nose), sneezing, and nasal itching. These are the symptoms the medicine is approved to manage.

How should Назофан be stored and disposed of?

Storage and Disposal of Fluticasone Propionate Nasal Spray

Storage Requirements

Fluticasone Propionate Nasal Spray (Назофан) must be stored at controlled room temperature, specifically between 4°C and 30°C (39°F and 86°F), to maintain its stability. The product must be protected from freezing and kept away from excess heat, moisture, and direct light. As a mandatory safety requirement, the spray must be kept out of the sight and reach of children.

Stability and Disposal Rules

For consistent dosage, the nasal spray unit must be discarded after the labeled number of metered sprays (typically 120) has been used, even if liquid remains. The medicine must not be used after the expiration date printed on the packaging. Disposal of unused or expired product should be carried out in accordance with applicable local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Belarus

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z